Cyclical stocks' strong run may be due a pause despite leading markets this year, leading bank warns

JP Morgan strategist Mislav Matejka says the year-to-date outperformance of cyclical stocks, value shares and small caps may be running ahead of economic reality. The rally has persisted even through the Iran conflict, which the firm describes as counterintuitive and potentially vulnerable if risk appetite fades. The note is a cautious warning on market leadership rather than a direct catalyst.

Analysis

The market is effectively pricing a soft-landing sequel before the macro data has earned it. Cyclicals and small caps can outperform early in an easing cycle, but the second-order risk is that investors are extrapolating a short-duration regime shift into a much slower-moving earnings cycle; that usually works until margins, not multiples, have to do the heavy lifting. If growth re-accelerates only modestly, the current leadership can persist; if growth merely normalizes without broadening, these groups are vulnerable because their balance sheets and refinancing needs make them more sensitive to even small downgrades.

The underappreciated loser is not just defensives, but any market segment reliant on stable discount rates and resilient input costs. Small caps and value are often crowded into domestic demand, higher beta financing, and lower quality earnings, so they can be hit hardest if geopolitics lifts energy prices or if risk premia reprice higher after a volatility shock. In that setup, the trade can unwind quickly over days, but the real damage would emerge over 1-3 months as analysts cut estimates and the market stops paying for an earnings recovery that is not showing up.

The contrarian view is that the rally may be less about conviction in growth than about positioning and factor exhaustion. If investors are underweight cyclicals after years of secular-growth leadership, even mediocre data can sustain the trade for a while. But once the market realizes the move is a valuation rerating rather than a true earnings inflection, leadership should narrow and late-cycle cyclicals become the first source of disappointment.

For JPM specifically, the message is mildly negative for near-term equity beta if their call is right, because the market is likely too comfortable with cyclical dispersion and too complacent on geopolitical tail risk. The higher-probability reversal trigger is not a recession headline, but a sequence of weaker PMIs, softer earnings guidance, or an energy shock that crimps consumer and industrial margins simultaneously.

Key Decisions for Investors

• Reduce long exposure to small-cap cyclicals over the next 2-4 weeks; use any further factor outperformance to fade via IWM puts or a partial hedge against high-beta domestic equity baskets.
• Pair trade: long defensives/quality balance sheets vs short cyclicals with refinancing risk for a 1-3 month horizon; prefer sectors with pricing power and low leverage over low-quality value.
• If holding value-factor exposure, cut gross and rotate toward names with visible free cash flow and low energy sensitivity; the risk/reward worsens if macro data fails to accelerate in the next 30-60 days.
• Consider a tactical short on JP Morgan-style cyclicals basket into strength if markets continue to price a full soft landing; stop if breadth broadens with improving earnings revisions and stable commodity prices.